Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
LungenClinic Grosshansdorf · Asklepios Fachkliniken München-Gauting · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
644
total citations
- FWCI
- 60.31
- Percentile
- 100%
- References
- 13
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Bevacizumab
- Medicine
- Gemcitabine
- Hazard ratio
- Clinical endpoint
- Internal medicine
- Placebo
- Lung cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.